Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Depreciation & Amortization (CF) (2020 - 2025)

Barinthus Biotherapeutics' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $909000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 36.34% year-over-year to $909000.0; the TTM value through Dec 2025 reached $5.8 million, up 0.78%, while the annual FY2025 figure was $5.8 million, 0.78% up from the prior year.
  • Depreciation & Amortization (CF) reached $909000.0 in Q4 2025 per BRNS's latest filing, up from $901000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.0 million in Q1 2025 to a low of $85000.0 in Q3 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.1 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 1297.65% in 2022, then crashed 38.92% in 2025.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $321000.0 in 2021, then skyrocketed by 266.67% to $1.2 million in 2022, then grew by 21.92% to $1.4 million in 2023, then fell by 0.49% to $1.4 million in 2024, then crashed by 36.34% to $909000.0 in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Depreciation & Amortization (CF) are $909000.0 (Q4 2025), $901000.0 (Q3 2025), and $2.0 million (Q2 2025).